Poboljšanje akcionog posthipoksičnog mioklonusa primenom dodatne terapije levetiracetamom

  • Ksenija Božić Clinic for Neurology, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Ksenija Gebauer-Bukurov Clinic for Neurology, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Lorand Sakalaš Clinic for Neurology, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Ivana Divjak Clinic for Neurology, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Aleksandar Ješić Clinic for Neurology, Clinical Center of Vojvodina, Novi Sad, Serbia
DOI: https://doi.org/10.2298/1343
Ključne reči: myoclonus||, ||mioklonus, anoxia||, ||anoksija, syndrome||, ||sindrom, diagnosis||, ||dijagnoza, drug therapy||, ||lečenje lekovima, drug resistance||, ||lekovi rezistencija, treatment outcome||, ||lečenje, ishod,

Sažetak



Uvod. Hronični postanoksični mioklonus, poznat i kao Lance-Adamsov sindrom, može se javiti nakon hipoksične povrede mozga i rezistentan je na farmakološku terapiju. Prikaz bolesnika. Prikazan je bolesnik sa postankosičnim mioklonusom i izraženim miokloničnim trzajevima koji su doveli do njegove potpune onesposobljenosti. Mioklonije nisu reagovale na uobičajene lekove kao što je valproat i klonazepam pojedinačno ili u kombinaciji. Poboljšanje akcionog mioklonusa postignuto je tek nakon uvođenja levetiracetama u dodatnoj terapiji. Zaključak. Iako još nije moguće potpuno izlečenje sindroma Lans-Adams, levetiracetat znatno popravlja funkcionalni i nivo ukupnog kvaliteta života bolesnika sa ovim poremećajem.


Reference

Lance JW, Adams RD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963; 86: 111−36.

Werhahn KJ, Brown P, Thompson PD, Marsden CD. The clinical features and prognosis of chronic posthypoxic myoclonus. Mov Disord 1997; 12(2): 216−20.

Borg M. Symptomatic myoclonus. Neurophysiol Clin 2006; 36(5−6): 309−18.

Frucht S, Fahn S. The clinical spectrum of posthypoxic myoc-lonus. Mov Disord 2000; 15(Suppl 1): 2−7.

Hallett M, Chadwick D, Adams J, Marsden CD. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry 1977; 40(3): 253−64.

Frucht SJ. The clinical challenge of posthypoxic myoclonus. Adv Neurol 2002; 89: 85–8.

Lance JW, Adams RD. Negative myoclonus in post-hypoxic pa-tients: historical note. Mov Disor 2001; 16(1): 162−3.

Truong DD, Kirby M, Kanthasamy A, Matsumoto RR. Posthypoxic myoclonus animal models. Adv Neurol 2002; 89: 295−306.

Matsumoto RR, Truong DD, Nguyen KD, Dang AT, Hoang TT, Vo PQ, et al. Involvement of GABA(A) receptors in myoclonus. Mov Disord 2000; 15 (Suppl 1): 47−52.

Tai KK, Truong DD. Post-hypoxic myoclonus induces Fos ex-pression in the reticualr thalamic nuclei and neurons in brains-tem. Brain Res 2005; 1059(2): 122−8.

Frucht SJ, Trost M, May Y, Eidelberg D. The metabolic topogra-phy of posthypoxic myoclonus. Neurology 2004; 62(10): 1879−81.

Witte OW, Niedermeyer E, Arendt G, Freund HJ. Post-hypoxic ac-tion (intention) myoclonus: a clinico-electroencephalographic study. J Neurol 1988; 235(4): 214−8.

Rollinson RD, Gilligan BS. Postanoxic action myoclonus (Lance Adams syndrome) responding to valproate. Arch Neurol 1979; 36(1): 44−5.

Frucht SJ. Myoclonus. Curr Treat Options Neurol 2000; 2(3): 231−42.

Polesin A, Stern M. Post-anoxic myoclonus: A case presentation and review of management in the rehabilitation setting. Brain Inj 2006; 20(2): 213−7.

Terwinghe G, Daumerie J, Nicaise C, Rosillon O. Therapeutic effect of piracetam in a case of posthypoxic action myoclonus. Acta Neurol Belg 1978; 8(1): 30−6. (French)

Obeso JA, Artieda J, Quinn N, Rothwell JC, Luquin MR, Vaamonde J, et al. Piracetam in the treatment of different types of myoc-lonus. Clin Neuropharmacol 1988; 11(6): 529−36.

Genton P, Guerrini R, Remy C. Piracetam in the treatment of cor-tical myoclonus. Pharmacopsychiatry 1999; 32(Suppl 1): 49−53.

Janszky J, Holló A, Halász P. Treatment and long term follow-up of post-anoxic myoclonus. Orv Hetil 2001; 142(38): 2091−3. (Hungarian)

Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epi-leptic Disord 2000; 2(4): 209−12.

Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoc-lonus of different etiologies. Parkinsonism Relat Disord 2005; 11(2): 135−7.

Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003; 107 (4): 302−3.

Yu HY, Kwan SY, Lirng JF, Liao KK, Chu YK, Liao SQ. Epilep-tic negative myoclonus: SPECT, PET, and video/EEG studies and the dramatic effects of levetiracetam. Epilepsy Behav 2009; 14(4): 687−90.

Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppres-sion of post-hypoxic and post-encephalitic myoclonus with le-vetiracetam. Neurology 2001; 56(3): 411−2.

Genton P, Gelisse P. Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 57(6): 1144−5.

Venot M, Weiss N, Espinoza S, Imbert A, Tadie JM, Fagon JY, et al. Improvement of early diagnosed post-anoxic myoclonus with levetiracetam. Intensive Care 2011; 37(1): 177−9.

Objavljeno
2015/04/23
Broj časopisa
Vol. 71 Br. 5 (2014)
Rubrika
Prikaz bolesnika